+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Kawasaki Disease Epidemiology Forecast 2025-2034

  • PDF Icon

    Report

  • 150 Pages
  • June 2025
  • Region: Global
  • Expert Market Research
  • ID: 6092334
Kawasaki disease or Kawasaki syndrome refers to a form of vasculitis that occurs most often in children between the ages of 6 months and 5 years. It is estimated that Kawasaki disease affects 50 to 250 per 100,000 children younger than 5 years in Japan, Taiwan, and Korea, as per the Cleveland Clinic. Kawasaki disease epidemiology forecast suggests that Kawasaki disease primarily affects children under five, with a higher incidence in males and those of Asian descent.

Kawasaki Disease Epidemiology Forecast Report Coverage

The “Kawasaki Disease Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of Kawasaki disease. It projects the future incidence and prevalence rates of Kawasaki disease cases across various populations. The study covers age and type as major determinants of the Kawasaki disease population. The report highlights patterns in the prevalence of Kawasaki disease over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on Kawasaki disease epidemiology in the 8 major markets.

Regions Covered

  • The United States
  • Germany
  • France
  • Italy
  • Spain
  • The United Kingdom
  • Japan
  • India

Kawasaki Disease Understanding: Disease Overview

Kawasaki disease (KD) causes inflammation in the walls of blood vessels throughout the body. It primarily affects young children, typically under the age of 5. The exact cause of the disease is unknown, but factors such as viral or bacterial infections, genetic predisposition, and environmental exposure are suggested to contribute to the development of the disease.

Kawasaki disease is one of the leading causes of acquired heart disease in children in developed countries. Studies show that early diagnosis and treatment with intravenous immunoglobulin (IVIG) and aspirin can significantly reduce the risk of coronary artery aneurysms. Common Kawasaki disease symptoms include fever lasting for more than five days, swollen lymph nodes (especially in the neck), and rash (often in the form of red spots or patches), among others.

Kawasaki Disease Epidemiology Perspective

The Kawasaki disease epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for the Kawasaki disease epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for Kawasaki Disease and their trends. The Kawasaki disease detailed epidemiology segmentation is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.
  • Kawasaki disease is reported to affect approximately 10 to 20 out of 100,000 children under 5 in the United States and Canada, according to the Cleveland Clinic. However, in Japan, Korea, and Taiwan, the Kawasaki disease incidence is significantly higher, ranging from 50 to 250 cases per 100,000 children under 5.
  • In North America, Europe, and Australia, the incidence of Kawasaki disease ranges from 5 to 22 cases per 100,000 children under the age of five. In these regions, incidence rates had been rising, primarily due to improved detection, until the last decade, during which the rates have stabilized, as per Lin, M. T., & Wu, M. H. (2017) and other studies.
  • Kawasaki disease is slightly more prevalent in males than females, with the male-to-female ratio varying between 1.3:1 and 1.83:1, depending on the country reporting the statistics.
  • Kawasaki disease is most frequently observed in children of Asian descent, particularly those of Japanese origin, and is least common among Caucasian children. Additionally, Kawasaki disease tends to be more prevalent in the winter and spring months, according to a 2017 review published in Circulation and other research studies.
  • In the United States, Kawasaki disease primarily affects children between 18 and 24 months, whereas in Japan, the Kawasaki disease incidence is highest among children aged 6 to 12 months.

Country-wise Kawasaki Disease Epidemiology Segment

The Kawasaki disease epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of Kawasaki disease varies significantly between countries due to differences in genetic factors, with higher prevalence rates in Asian populations. Environmental factors such as seasonal infections and healthcare access also influence incidence rates. Japan has reported the highest incidence of Kawasaki disease. Studies show that the incidence of Kawasaki disease in Japan is 10 to 20 times higher than in Western countries.

Kawasaki Disease: Treatment Overview

Intravenous immunoglobulin (IVIG) is the primary treatment of Kawasaki disease and should be administered within the first 10 days of illness. IVIG helps reduce inflammation and the abnormal immune response causing the disease, with most children showing a good recovery rate. Aspirin is also used carefully under a doctor's supervision because of its benefits in preventing coronary complications.

In Kawasaki disease cases where patients do not respond to IVIG therapy or those with more severe symptoms, corticosteroids like prednisone are prescribed. Biologic agents, such as infliximab (a TNF-a inhibitor) or anakinra (an IL-1 receptor antagonist), may be considered for refractory cases or in Kawasaki disease patients at high risk for IVIG resistance. Cyclosporine and other immunosuppressants may be used in severe or persistent cases, particularly when other therapies fail.

Key Questions Answered

  • What are the key findings of Kawasaki disease epidemiology in the 8 major markets?
  • What will be the total number of patients with Kawasaki disease across the 8 major markets during the forecast period?
  • What was the country-wise Kawasaki disease epidemiology scenario in the 8 major markets in the historical period?
  • Which country will have the highest number of Kawasaki disease cases during the forecast period of 2025-2034?
  • Which key factors would influence the shift in the patient population of Kawasaki disease during the forecast period of 2025-2034?
  • What are the currently available treatments in the global Kawasaki disease market?
  • What are the disease risks, signs, symptoms, and unmet needs of Kawasaki disease?

Scope of the Kawasaki Disease Epidemiology Report

  • The Kawasaki disease epidemiology forecast covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of Kawasaki Disease based on several factors.
  • The Kawasaki Disease Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
  • The Kawasaki disease report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

This product will be delivered within 3-5 business days.

Table of Contents

1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology and Assumptions
2 Executive Summary
3 Kawasaki Disease Market Overview - 8 MM
3.1 Kawasaki Disease Market Historical Value (2018-2024)
3.2 Kawasaki Disease Market Forecast Value (2025-2034)
4 Kawasaki Disease Epidemiology Overview - 8 MM
4.1 Kawasaki Disease Epidemiology Scenario (2018-2024)
4.2 Kawasaki Disease Epidemiology Forecast
5 Disease Overview
5.1 Signs and Symptoms
5.2 Causes
5.3 Risk Factors
5.4 Guidelines and Stages
5.5 Pathophysiology
5.6 Screening and Diagnosis
6 Patient Profile
6.1 Patient Profile Overview
6.2 Patient Psychology and Emotional Impact Factors
7 Epidemiology Scenario and Forecast - 8 MM
7.1 Key Findings
7.2 Assumptions and Rationale
7.3 Kawasaki Disease Epidemiology Scenario in 8MM (2018-2034)
8 Epidemiology Scenario and Forecast: United States
8.1 Kawasaki Disease Epidemiology Scenario and Forecast in The United States (2018-2034)
9 Epidemiology Scenario and Forecast: United Kingdom
9.1 Kawasaki Disease Epidemiology Scenario and Forecast in United Kingdom (2018-2034)
10 Epidemiology Scenario and Forecast: Germany
10.1 Kawasaki Disease Epidemiology Scenario and Forecast in Germany (2018-2034)
11 Epidemiology Scenario and Forecast: France
11.1 Kawasaki Disease Epidemiology Scenario and Forecast in France
12 Epidemiology Scenario and Forecast: Italy
12.1 Kawasaki Disease Epidemiology Scenario and Forecast in Italy (2018-2034)
13 Epidemiology Scenario and Forecast: Spain
13.1 Kawasaki Disease Epidemiology Scenario and Forecast in Spain (2018-2034)
14 Epidemiology Scenario and Forecast: Japan
14.1 Kawasaki Disease Epidemiology Scenario and Forecast in Japan (2018-2034)
15 Epidemiology Scenario and Forecast: India
15.1 Kawasaki Disease Epidemiology Scenario and Forecast in India (2018-2034)
16 Patient Journey17 Treatment Challenges and Unmet Needs18 Key Opinion Leaders (KOL) Insights